AUROPHARMA Stock Overview
A biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Aurobindo Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,241.70 |
| 52 Week High | ₹1,592.00 |
| 52 Week Low | ₹958.50 |
| Beta | 0.63 |
| 1 Month Change | 1.78% |
| 3 Month Change | -17.02% |
| 1 Year Change | 16.44% |
| 3 Year Change | 75.27% |
| 5 Year Change | 168.13% |
| Change since IPO | 1,754.81% |
Recent News & Updates
Is Aurobindo Pharma (NSE:AUROPHARMA) Using Too Much Debt?
Dec 18
Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts
Nov 12Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price
Oct 20Recent updates
Is Aurobindo Pharma (NSE:AUROPHARMA) Using Too Much Debt?
Dec 18Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts
Nov 12Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price
Oct 20Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Sep 10This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet
Aug 23Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422
Aug 13Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly
Jun 20Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271
May 29Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
May 22Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors
Apr 10Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?
Jan 14Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27Shareholder Returns
| AUROPHARMA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.8% | 0.8% | -4.2% |
| 1Y | 16.4% | 39.7% | 19.1% |
Return vs Industry: AUROPHARMA underperformed the Indian Pharmaceuticals industry which returned 39.7% over the past year.
Return vs Market: AUROPHARMA underperformed the Indian Market which returned 19.1% over the past year.
Price Volatility
| AUROPHARMA volatility | |
|---|---|
| AUROPHARMA Average Weekly Movement | 3.1% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: AUROPHARMA has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: AUROPHARMA's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 26,015 | Kambam Reddy | www.aurobindo.com |
Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams.
Aurobindo Pharma Limited Fundamentals Summary
| AUROPHARMA fundamental statistics | |
|---|---|
| Market cap | ₹721.18b |
| Earnings (TTM) | ₹35.82b |
| Revenue (TTM) | ₹302.95b |
20.1x
P/E Ratio2.4x
P/S RatioIs AUROPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AUROPHARMA income statement (TTM) | |
|---|---|
| Revenue | ₹302.95b |
| Cost of Revenue | ₹128.77b |
| Gross Profit | ₹174.18b |
| Other Expenses | ₹138.36b |
| Earnings | ₹35.82b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 61.67 |
| Gross Margin | 57.49% |
| Net Profit Margin | 11.82% |
| Debt/Equity Ratio | 26.2% |
How did AUROPHARMA perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield2%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 20:59 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aurobindo Pharma Limited is covered by 54 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Meeta Shetty | Asian Markets Securities Private Limited |
| Kamlesh Kotak | Asian Markets Securities Private Limited |
| Harith Ahamed | Avendus Spark |